alanine has been researched along with Glucose Intolerance in 13 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-alanine (Ala) and L-arginine (Arg) have been reported to regulate pancreatic β-cell physiology and to prevent body fat accumulation in diet-induced obesity." | 7.85 | Benefits of L-alanine or L-arginine supplementation against adiposity and glucose intolerance in monosodium glutamate-induced obesity. ( Araujo, TR; Balbo, SL; Batista, TM; Bonfleur, ML; Boschero, AC; Carneiro, EM; Freitas, IN; Ribeiro, RA; Santos-Silva, JC; Vettorazzi, JF, 2017) |
| "(a) A higher incidence of preeclampsia was observed in abnormal glucose tolerance patients, (b) total homocysteine and alanine were the only individual amino acids whose plasma concentrations varied according to the glucose tolerance classes, and (c) an association between hyperhomocysteinemia and glucose intolerance in our preeclamptic patients could not be demonstrated." | 7.73 | Are plasma total homocysteine and other amino acids associated with glucose intolerance in uncomplicated pregnancies and preeclampsia? ( Antònia Vilaseca, M; Gómez, E; Lailla, JM; López-Quesada, E, 2005) |
| "L-alanine (Ala) and L-arginine (Arg) have been reported to regulate pancreatic β-cell physiology and to prevent body fat accumulation in diet-induced obesity." | 3.85 | Benefits of L-alanine or L-arginine supplementation against adiposity and glucose intolerance in monosodium glutamate-induced obesity. ( Araujo, TR; Balbo, SL; Batista, TM; Bonfleur, ML; Boschero, AC; Carneiro, EM; Freitas, IN; Ribeiro, RA; Santos-Silva, JC; Vettorazzi, JF, 2017) |
| "(a) A higher incidence of preeclampsia was observed in abnormal glucose tolerance patients, (b) total homocysteine and alanine were the only individual amino acids whose plasma concentrations varied according to the glucose tolerance classes, and (c) an association between hyperhomocysteinemia and glucose intolerance in our preeclamptic patients could not be demonstrated." | 3.73 | Are plasma total homocysteine and other amino acids associated with glucose intolerance in uncomplicated pregnancies and preeclampsia? ( Antònia Vilaseca, M; Gómez, E; Lailla, JM; López-Quesada, E, 2005) |
| "The risk for type 2 diabetes increased also in subjects who gained weight or belonged to the control group." | 2.70 | Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. ( Eriksson, JG; Hämäläinen, H; Ilanne-Parikka, P; Keinänen-Kiukaanniemi, S; Laakso, M; Lindi, VI; Lindström, J; Louheranta, A; Tuomilehto, J; Uusitupa, MI; Valle, TT, 2002) |
| "Insulin resistance was evaluated with fasting insulin, fasting glucose/insulin ratio, and homeostasis model assessment index for insulin resistance (HOMAIR)." | 1.33 | Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. ( Gong, KB; Ku, DC; Kuo, TC; Liang, SF; Lin, TC; Wu, MJ; Yen, JM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 1 |
| Dong, M | 1 |
| Yuan, S | 1 |
| Jin, W | 1 |
| Bae, EJ | 1 |
| Choi, WG | 1 |
| Pagire, HS | 1 |
| Pagire, SH | 1 |
| Parameswaran, S | 1 |
| Choi, JH | 1 |
| Yoon, J | 1 |
| Choi, WI | 1 |
| Lee, JH | 1 |
| Song, JS | 1 |
| Bae, MA | 1 |
| Kim, M | 1 |
| Jeon, JH | 1 |
| Lee, IK | 1 |
| Kim, H | 1 |
| Ahn, JH | 1 |
| Araujo, TR | 1 |
| Freitas, IN | 1 |
| Vettorazzi, JF | 1 |
| Batista, TM | 1 |
| Santos-Silva, JC | 1 |
| Bonfleur, ML | 1 |
| Balbo, SL | 1 |
| Boschero, AC | 1 |
| Carneiro, EM | 1 |
| Ribeiro, RA | 1 |
| Nakanishi, S | 1 |
| Yamane, K | 1 |
| Ohishi, W | 1 |
| Nakashima, R | 1 |
| Yoneda, M | 1 |
| Nojima, H | 1 |
| Watanabe, H | 1 |
| Kohno, N | 1 |
| Bokhari, S | 1 |
| Emerson, P | 1 |
| Israelian, Z | 1 |
| Gupta, A | 1 |
| Meyer, C | 1 |
| Galazis, N | 1 |
| Iacovou, C | 1 |
| Haoula, Z | 1 |
| Atiomo, W | 1 |
| Lindi, VI | 1 |
| Uusitupa, MI | 1 |
| Lindström, J | 1 |
| Louheranta, A | 1 |
| Eriksson, JG | 1 |
| Valle, TT | 1 |
| Hämäläinen, H | 1 |
| Ilanne-Parikka, P | 1 |
| Keinänen-Kiukaanniemi, S | 1 |
| Laakso, M | 1 |
| Tuomilehto, J | 1 |
| López-Quesada, E | 1 |
| Antònia Vilaseca, M | 1 |
| Gómez, E | 1 |
| Lailla, JM | 1 |
| Ishii, T | 1 |
| Hirose, H | 1 |
| Lin, TC | 1 |
| Yen, JM | 1 |
| Gong, KB | 1 |
| Kuo, TC | 1 |
| Ku, DC | 1 |
| Liang, SF | 1 |
| Wu, MJ | 1 |
| Hardin, DS | 1 |
| Ahn, C | 1 |
| Rice, J | 1 |
| Rice, M | 1 |
| Rosenblatt, R | 1 |
| Oh, EY | 1 |
| Min, KM | 1 |
| Chung, JH | 1 |
| Min, YK | 1 |
| Lee, MS | 1 |
| Kim, KW | 1 |
| Lee, MK | 1 |
| Krentz, AJ | 1 |
| Singh, BM | 1 |
| Hale, PJ | 1 |
| Robertson, DA | 1 |
| Nattrass, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications[NCT00518167] | 522 participants (Actual) | Interventional | 1993-11-30 | Active, not recruiting | |||
| Increased Gluconeogenesis is One Cause of CFRD[NCT00082238] | 42 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
2 reviews available for alanine and Glucose Intolerance
| Article | Year |
|---|---|
Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome.
Topics: Adult; Alanine; Biomarkers; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypergly | 2012 |
[Fatty acid binding protein-2 (FABP2) gene polymorphism in diabetes].
Topics: Adipocytes; Alanine; Amino Acid Substitution; Carrier Proteins; Diabetes Mellitus; Fatty Acid-Bindin | 2005 |
1 trial available for alanine and Glucose Intolerance
| Article | Year |
|---|---|
Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study.
Topics: Alanine; Amino Acid Substitution; Blood Glucose; Body Constitution; Body Mass Index; Body Weight; Di | 2002 |
10 other studies available for alanine and Glucose Intolerance
| Article | Year |
|---|---|
Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice.
Topics: Alanine; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Pe | 2022 |
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease.
Topics: Adiposity; Alanine; Animals; Anti-Obesity Agents; Diet, High-Fat; Energy Metabolism; Enzyme Inhibito | 2021 |
Benefits of L-alanine or L-arginine supplementation against adiposity and glucose intolerance in monosodium glutamate-induced obesity.
Topics: Adiposity; Alanine; Animals; Arginine; Blood Glucose; Cholesterol; Dietary Supplements; Gene Express | 2017 |
Manganese superoxide dismutase Ala16Val polymorphism is associated with the development of type 2 diabetes in Japanese-Americans.
Topics: Alanine; Amino Acid Substitution; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose To | 2008 |
Metabolic fate of plasma glucose during hyperglycemia in impaired glucose tolerance: evidence for further early defects in the pathogenesis of type 2 diabetes.
Topics: Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glu | 2009 |
Are plasma total homocysteine and other amino acids associated with glucose intolerance in uncomplicated pregnancies and preeclampsia?
Topics: Adult; Alanine; Amino Acids; Diabetes, Gestational; Female; Glucose Intolerance; Homocysteine; Human | 2005 |
Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism.
Topics: Adolescent; Adult; Alanine; Amino Acid Substitution; Arginine; Diabetes Mellitus; Female; Glucose In | 2006 |
Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes.
Topics: Adult; Alanine; Carbon Isotopes; Cystic Fibrosis; Deuterium; Diabetes Mellitus, Type 2; Female; Gluc | 2008 |
Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects.
Topics: Alanine; Amino Acid Substitution; Asian People; Body Mass Index; Diabetes Mellitus; Female; Genotype | 2000 |
Basal intermediary metabolism in impaired glucose tolerance and morbid obesity.
Topics: Adult; Alanine; Analysis of Variance; Blood Glucose; C-Peptide; Fatty Acids, Nonesterified; Female; | 1992 |